SISI, MONIA
SISI, MONIA
Borsisti
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D.
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination
2021 Gelsomino F.; Facchinetti F.; Sisi M.; Zielli T.; Tiseo M.; Ardizzoni A.
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
2022 Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution
2021 Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A.
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication
2020 Lamberti G.; Andrini E.; Sisi M.; Di Federico A.; Ricciuti B.
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?
2020 Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F.